OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple Turns 50: From Garage Startup to AI Crossroads 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
ST. HELIER, Jersey, Sept. 30, 2016 -- Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended Sept. 30, 2016, at 8 a.m. EDT on Wednesday, Nov. 2, 2016.
The conference call can be accessed by dialing 877-726-5929 for domestic callers and 530-379-4648 for international callers, using the conference ID 76871474. The webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investors, and will be available for replay for at least 14 days following the call.
About Novocure
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
Media and Investor Contact: Ashley Cordova 212-767-7558 [email protected]
